{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T23:09:43Z","timestamp":1794784183048,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>SWOG S0777, a randomized phase III trial, compared bortezomib, lenalidomide and dexamethasone (VRd) with lenalidomide and dexamethasone (Rd). This updated analysis includes 460 patients evaluable for survival endpoints: 225 eligible and analyzable patients were randomized to Rd and 235 to VRd. The 6-month induction was six 28-day cycles of Rd and eight 21-day cycles of VRd followed by Rd maintenance for all patients. Median follow up is 84 months. Median PFS is 41 months for VRd and 29 months for Rd: stratified hazard ratio (96% Wald Confidence Interval) was 0.742 (0.594, 0.928) and one-sided stratified log-rank<jats:italic>P<\/jats:italic>-value 0.003. Median OS for VRd is still not reached with median OS for Rd being 69 months: stratified hazard ratio (96% Wald Confidence Interval) was 0.709 (0.543, 0.926) and stratified two-sided<jats:italic>P<\/jats:italic>-value was 0.0114. Both PFS and OS were improved with VRd versus Rd adjusting for age (<jats:italic>P<\/jats:italic>-values: 0.013 [PFS]; 0.033 [OS])). Median duration of Rd maintenance was 17.1 months. The addition of bortezomib to lenalidomide dexamethasone for induction therapy results in a statistically significant and clinically meaningful improvement in PFS as well as better OS. VRd continues to represent an appropriate standard of care irrespective of age.<\/jats:p>","DOI":"10.1038\/s41408-020-0311-8","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T15:08:15Z","timestamp":1589209695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":205,"title":["Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)"],"prefix":"10.1038","volume":"10","author":[{"given":"Brian G. M.","family":"Durie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Hoering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneer H.","family":"Abidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Kahanic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan C.","family":"Thakuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic J.","family":"Reu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,11]]},"reference":[{"key":"311_CR1","unstructured":"Anonymous Revlimid\u00ae (lenalidomide) [prescribing information]. (Celgene Corporation, Summit, 2017)."},{"key":"311_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305\u2013309 (2014).","journal-title":"Science"},{"key":"311_CR3","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona, A. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26, 2326\u20132335 (2012).","journal-title":"Leukemia"},{"key":"311_CR4","first-page":"215","volume":"4","author":"P Richardson","year":"2010","unstructured":"Richardson, P. et al. Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 4, 215\u2013245 (2010).","journal-title":"Core Evid."},{"key":"311_CR5","unstructured":"Anonymous Velcade [package insert]. (Millenium Pharmaceuticals, Cambridge, MA, 2017)."},{"key":"311_CR6","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","volume":"101","author":"T Hideshima","year":"2003","unstructured":"Hideshima, T. et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101, 1530\u20131534 (2003).","journal-title":"Blood"},{"key":"311_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1756-8722-2-36","volume":"2","author":"V Kotla","year":"2009","unstructured":"Kotla, V. et al. Mechanism of action of lenalidomide in hematological malignancies. J. Hematol. Oncol. 2, 36 (2009).","journal-title":"J. Hematol. Oncol."},{"key":"311_CR8","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","volume":"99","author":"N Mitsiades","year":"2002","unstructured":"Mitsiades, N. et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99, 4525\u20134530 (2002).","journal-title":"Blood"},{"key":"311_CR9","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima, T. et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071\u20133076 (2001).","journal-title":"Cancer Res."},{"key":"311_CR10","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar, S. V. et al. Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma. Blood 106, 4050\u20134053 (2005).","journal-title":"Blood"},{"key":"311_CR11","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1038\/leu.2009.147","volume":"23","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos, M. A. et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23, 2147\u20132152 (2009).","journal-title":"Leukemia"},{"key":"311_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3324\/haematol.2014.112037","volume":"100","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos, M. A. et al. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica 100, 100\u2013106 (2015).","journal-title":"Haematologica"},{"key":"311_CR13","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1182\/blood-2013-07-517276","volume":"123","author":"PG Richardson","year":"2014","unstructured":"Richardson, P. G. et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed\/refractory myeloma. Blood 123, 1461\u20131469 (2014).","journal-title":"Blood"},{"key":"311_CR14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson, P. G. et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116, 679\u2013686 (2010).","journal-title":"Blood"},{"key":"311_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie, B. G. et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389, 519\u2013527 (2017).","journal-title":"Lancet"},{"key":"311_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/sj.thj.6200312","volume":"4","author":"BG Durie","year":"2003","unstructured":"Durie, B. G. et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hemtatol. J. 4, 379\u2013398 (2003).","journal-title":"Hemtatol. J."},{"key":"311_CR17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken, M. M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649\u2013655 (1982).","journal-title":"Am. J. Clin. Oncol."},{"key":"311_CR18","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Griepp","year":"2005","unstructured":"Griepp, P. R. et al. International staging system for multiple myeloma. J. Clin. Oncol. 23, 3412\u20133420 (2005).","journal-title":"J. Clin. Oncol."},{"key":"311_CR19","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie, B. G. et al. International uniform response criteria for multiple myeloma. Leukemia 20, 1467\u20131473 (2006).","journal-title":"Leukemia"},{"key":"311_CR20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/bjc.1976.220","volume":"34","author":"R Peto","year":"1976","unstructured":"Peto, R. et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient: I. Introduction and design. Br. J. Cancer 34, 585\u2013612 (1976).","journal-title":"Br. J. Cancer"},{"key":"311_CR21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1259\/0007-1285-44-526-793","volume":"44","author":"JL Haybittle","year":"1971","unstructured":"Haybittle, J. L. Repeated assessment of results in clinical trials of cancer treatment. Br. J. Radiol. 44, 793\u2013797 (1971).","journal-title":"Br. J. Radiol."},{"key":"311_CR22","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50, 163\u2013170 (1966).","journal-title":"Cancer Chemother. Rep."},{"key":"311_CR23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"B34","author":"DR Cox","year":"1972","unstructured":"Cox, D. R. Regression models and life tables (with discussion). J. R. Stat. Soc. B34, 187\u2013220 (1972).","journal-title":"J. R. Stat. Soc."},{"key":"311_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan, E. L. & Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457\u2013481 (1958).","journal-title":"J. Am. Stat. Assoc."},{"key":"311_CR25","doi-asserted-by":"crossref","unstructured":"Agresti, Alan. Categorical Data Analysis, 2nd edn (John Wiley & Sons, New York, 2002).","DOI":"10.1002\/0471249688"},{"key":"311_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2307\/3001616","volume":"10","author":"WG Cochran","year":"1954","unstructured":"Cochran, W. G. Some methods for strengthening the common tests. Biometrics 10, 417\u2013451 (1954).","journal-title":"Biometrics"},{"key":"311_CR27","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel, N. & Haenszel, W. Statistical aspects of analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22, 719\u2013748 (1959).","journal-title":"J. Natl. Cancer Inst."},{"key":"311_CR28","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"M Cavo","year":"2010","unstructured":"Cavo, M. et al. GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376, 2075\u20132085 (2010).","journal-title":"Lancet"},{"key":"311_CR29","unstructured":"Moreau, P. et al. Bortezomib, thalidomide and dexamethasone (VTD) is superior to bortezomib, cyclophosphamide and dexamethasone (VCD) prior to autologous stem cell transplantation for patients with de novo multiple myeloma: results of the prospective IFM 2013-2014 [ASH Annual Meeting Abstracts 2015, abstract 393]. American Society of Hematology website. https:\/\/ash.confex.com\/ash\/2015\/webprogram\/Paper81103.html. Accessed 10 Nov 2015."},{"key":"311_CR30","first-page":"679","volume":"116","author":"AJ Jakubowiak","year":"2010","unstructured":"Jakubowiak, A. J. et al. A phase \u00bd study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as frontline treatment for multiple myeloma. Blood 116, 679\u2013686 (2010).","journal-title":"Blood"},{"key":"311_CR31","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy, P. L. et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J. Clin. Oncol. 35, 3279\u20133289 (2017).","journal-title":"J. Clin. Oncol."},{"key":"311_CR32","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal, M. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. New Engl. J. Med. 376, 1311\u20131320 (2017).","journal-title":"New Engl. J. Med."},{"key":"311_CR33","doi-asserted-by":"crossref","unstructured":"Facon, T. et al. Phase 3 Randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA); ASH 2018. Abstract LBA-2.","DOI":"10.1182\/blood-2018-120737"},{"key":"311_CR34","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon, T. et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N. Engl. J. Med. 380, 2104\u20132115 (2019).","journal-title":"N. Engl. J. Med."},{"key":"311_CR35","first-page":"339","volume":"16","author":"P Kapoor","year":"2019","unstructured":"Kapoor, P. & Rajkumar, V. MAIA under the microscope\u2014bringing trial design into focus. Nat. Rev.: Clin. Oncol. 16, 339\u2013340 (2019).","journal-title":"Nat. Rev.: Clin. Oncol."},{"key":"311_CR36","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1182\/blood.2019000241","volume":"134","author":"L Rosi\u00f1ol","year":"2019","unstructured":"Rosi\u00f1ol, L. et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood 134, 1337\u20131345 (2019).","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0311-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0311-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0311-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T17:33:18Z","timestamp":1722879198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0311-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,11]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["311"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-0311-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,11]]},"assertion":[{"value":"22 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.G.M.D.: Johnson & Johnson: Consultancy; Takeda: Consultancy; Onyx: Consultancy; Celgene: Consultancy. M.H.A.: Millennium: Research Funding. J.E.: University of Arkansas for Medical Sciences: Employment. F.J.R.: Takeda\/Millennium: Research Funding; Novartis: Research Funding; Celgene: Research Funding. R.Z.O: BioTheryX, Inc.: Membership on an entity\u2019s Board of Directors or advisory committees; Janssen Pharmaceuticals: Membership on an entity\u2019s Board of Directors or advisory committees; Celgene: Consultancy, Research Funding; Spectrum Pharmaceuticals: Research Funding; Onyx Pharmaceuticals: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Millennium Pharmaceuticals: Consultancy, Research Funding; Acetylon: Membership on an entity\u2019s Board of Directors or advisory committees; Genentech: Consultancy; Forma Therapeutics: Consultancy; Array BioPharma: Consultancy, Research Funding. B.B.: Dana Farber Cancer Institute: Other: Travel Stipend; International Workshop on Waldenstr\u00f6m\u2019s Macroglobulinemia: Other: Travel Stipend; ComtecMed-World Congress on Controversies in Hematology: Other: Travel Stipend; European School of Hematology- International Conference on Multiple Myeloma: Other: Travel Stipend; Celgene: Consultancy, Research Funding; Millennium: Consultancy, Research Funding; Myeloma Health, LLC: Patents & Royalties: Co-inventor of patents and patent applications related to use of GEP in cancer medicine licensed to Myeloma Health, LLC; Multiple Myeloma Research Foundation: Other: Travel Stipend.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"53"}}